Genprex, Inc. (GNPX) Form 8-K — Aug 5, 2026
Genprex announced that the Nasdaq Hearings Panel determined the company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), formally resolving the delisting threat disclosed on July 29, 2026. Under the exception, Genprex must maintain a closing bid price at or above $1.00 for each trading day, and the Panel will retain jurisdiction over the company until December 7, 2026. If Genprex becomes non-compliant with any other Nasdaq listing rule before December 7, 2026, it will have only seven calendar days to present a cure plan, and the Panel can then either grant an exception or delist the stock.
Key figures
- Panel jurisdiction end date
- December 7, 2026
- Cure period other violations
- 7 calendar days
- Panel exception granted date
- 2026-07-29
- Minimum bid price requirement
- $1.00
- Compliance regained notice date
- 2026-08-04
Price after filing
Close on the filing date to close N calendar days later (from $4.44). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.